Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.

Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M.

J Clin Oncol. 2007 Apr 1;25(10):1247-54. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262.

PMID:
17401013
2.

The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.

Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW.

Cancer Chemother Pharmacol. 2010 Aug;66(3):493-500. doi: 10.1007/s00280-009-1186-3. Epub 2009 Dec 4.

PMID:
19960344
3.

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.

Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L, Flesch M, Carola E, de Gramont A.

Br J Clin Pharmacol. 2010 Jan;69(1):58-66. doi: 10.1111/j.1365-2125.2009.03556.x.

4.

Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.

Martinez-Balibrea E, Abad A, Aranda E, Sastre J, Manzano JL, Díaz-Rubio E, Gómez-España A, Aparicio J, García T, Maestu I, Martínez-Cardús A, Ginés A, Guino E; Spanish Group for the Treatment of Digestive Tumours.

Eur J Cancer. 2008 Jun;44(9):1229-37. doi: 10.1016/j.ejca.2008.03.025. Epub 2008 Apr 28.

PMID:
18448328
5.

Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.

Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, Bisonni R, Canestrari E, Ficarelli R, Menichetti ET, Mari D, Testa E, Silva R, Vincenzi B, Giordani P, Cascinu S, Giustini L, Tonini G, Magnani M.

J Clin Oncol. 2006 Apr 20;24(12):1883-91.

PMID:
16622263
6.

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.

Paré L, Marcuello E, Altés A, del Río E, Sedano L, Salazar J, Cortés A, Barnadas A, Baiget M.

Br J Cancer. 2008 Oct 7;99(7):1050-5. doi: 10.1038/sj.bjc.6604671. Epub 2008 Sep 16. Erratum in: Br J Cancer. 2009 Apr 21;100(8):1368.

7.

Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.

Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, Jaeger E, Bokemeyer C, Ehninger G, Stoehlmacher J.

J Clin Oncol. 2009 Jun 10;27(17):2863-73. doi: 10.1200/JCO.2008.19.1718. Epub 2009 Mar 30.

PMID:
19332728
8.

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F.

Clin Cancer Res. 2005 Sep 1;11(17):6212-7.

9.

Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.

Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.

Am J Clin Oncol. 2009 Feb;32(1):38-43. doi: 10.1097/COC.0b013e31817be58e.

PMID:
19194123
10.

Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.

Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS.

Cancer Sci. 2010 Feb;101(2):530-5. doi: 10.1111/j.1349-7006.2009.01418.x. Epub 2009 Oct 28.

11.

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.

Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Heo DS, Kim WH, Bang YJ.

BMC Cancer. 2008 May 27;8:148. doi: 10.1186/1471-2407-8-148.

12.
13.

Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.

Monzo M, Moreno I, Navarro A, Ibeas R, Artells R, Gel B, Martinez F, Moreno J, Hernandez R, Navarro-Vigo M.

Oncology. 2007;72(5-6):364-70. doi: 10.1159/000113534. Epub 2008 Jan 17.

PMID:
18204222
14.

Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.

Lai JI, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS.

Cancer Sci. 2009 Jul;100(7):1261-6. doi: 10.1111/j.1349-7006.2009.01186.x. Epub 2009 May 4.

15.

A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.

Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ.

Cancer Res. 2001 Dec 15;61(24):8654-8.

16.

Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.

Páez D, Salazar J, Paré L, Pertriz L, Targarona E, del Rio E, Barnadas A, Marcuello E, Baiget M.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1319-27. doi: 10.1016/j.ijrobp.2011.01.025. Epub 2011 May 11.

PMID:
21570215
17.

ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.

Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ.

Clin Adv Hematol Oncol. 2003 Mar;1(3):162-6.

PMID:
16224397
18.

Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.

Fernández-Contreras ME, Sánchez-Hernández JJ, González E, Herráez B, Domínguez I, Lozano M, García De Paredes ML, Muñoz A, Gamallo C.

Int J Oncol. 2009 Jan;34(1):219-29.

19.

The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.

Huang ZH, Hua D, Li LH.

Cancer Chemother Pharmacol. 2009 Apr;63(5):911-8. doi: 10.1007/s00280-008-0815-6. Epub 2008 Aug 15.

PMID:
18704422
20.

ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.

Lu X, Xiao S, Jin C, van der Straaten T, Li X.

J Clin Lab Anal. 2012 Jan;26(1):10-5. doi: 10.1002/jcla.20494.

PMID:
24833529

Supplemental Content

Support Center